Table 2.
Multivariate regression models according to HF stages
| Multivariate linear regression models according to HF stages | |||
| Estimate | 95% CI | P value | |
| Age | <0.001 | ||
| HF stage A | Ref | ||
| HF stage B | 3.55 | 2.137 to 4.956 | <0.001 |
| HF stage C | 3.33 | 1.525 to 5.128 | <0.001 |
| Diastolic blood pressure | <0.001 | ||
| HF stage A | Ref | ||
| HF stage B | −0.09 | −2.291 to 2.106 | 0.934 |
| HF stage C | −1.87 | −4.640 to 0.901 | 0.185 |
| Minnesota Living with Heart Failure Questionnaire | 0.049 | ||
| HF stage A | Ref | ||
| HF stage B | −6.11 | −10.32 to 1.89 | 0.005 |
| HF stage C | 12.33 | 7.18 to 17.56 | <0.001 |
| Framingham 4-year risk of congestion | 0.118 | ||
| HF stage A | Ref | ||
| HF stage B | 0.36 | −0.33 to 1.05 | 0.306 |
| HF stage C | 0.61 | −0.26 to 1.48 | 0.17 |
| Haemoglobin | <0.001 | ||
| HF stage A | Ref | ||
| HF stage B | −0.06 | −0.26 to 0.14 | 0.528 |
| HF stage C | −0.15 | −0.41 to 0.10 | 0.232 |
| eGFR | <0.001 | ||
| HF stage A | Ref | ||
| HF stage B | −1.36 | −5.25 to 2.54 | 0.495 |
| HF stage C | −2.77 | −7.67 to 2.14 | 0.269 |
| Bilirubin | <0.001 | ||
| HF stage A | Ref | ||
| HF stage B | 1.04 | −0.08 to 2.17 | 0.069 |
| HF stage C | 1.1 | −0.32 to 2.52 | 0.128 |
| Albumin | <0.001 | ||
| HF stage A | Ref | ||
| HF stage B | −0.65 | −1.39 to 0.09 | 0.084 |
| HF stage C | −0.84 | −1.76 to 0.09 | 0.077 |
| NT-proBNP | <0.001 | ||
| HF stage A | Ref | ||
| HF stage B | 0.34 | 0.02 to 0.66 | 0.036 |
| HF stage C | 0.87 | 0.48 to 1.28 | <0.001 |
| MR-proADM | <0.001 | ||
| HF stage A | Ref | ||
| HF stage B | 0.07 | −0.03 to 0.17 | 0.179 |
| HF stage C | 0.29 | 0.16 to 0.42 | <0.001 |
| Copeptin | 0.009 | ||
| HF stage A | Ref | ||
| HF stage B | 0.16 | −0.15 to 0.35 | 0.422 |
| HF stage C | 0.16 | 0.11 to 0.74 | 0.008 |
| Multivariate logistic regression models according to HF stages | |||
| OR | 95% CI | P value | |
| Left branch bundle block on ECG | 0.217 | ||
| HF stage A vs HF stage B | 6.44 | 0.68 to 60.56 | 0.104 |
| HF stage A vs HF stage C | 8.16 | 0.74 to 90.51 | 0.087 |
| NYHA class | |||
| HF stage A vs HF stage B | 1.21 | 0.74 to 1.99 | 0.446 |
| HF stage A vs HF stage C | 0.29 | 0.16 to 0.52 | <0.001 |
| Atrial fibrillation | <0.001 | ||
| HF stage A vs HF stage B | 1.48 | 0.78 to 2.80 | 0.227 |
| HF stage A vs HF stage C | 2.39 | 1.12 to 5.10 | 0.024 |
| Microalbuminuria | 0.008 | ||
| HF stage A vs HF stage B | 1.35 | 0.82 to 2.25 | 0.241 |
| HF stage A vs HF stage C | 1.3 | 0.69 to 2.44 | 0.412 |
| Troponin-I ≥10 ng/L | 0.01 | ||
| HF stage A vs HF stage B | 2.35 | 1.21 to 4.54 | 0.011 |
| HF stage A vs HF stage C | 2.55 | 1.18 to 5.50 | 0.017 |
The response variables are specified below. The predictor variables are HF stages, age, gender, atrial fibrillation, hypertension, ischaemic heart disease, stroke, diabetes, kidney function (eGFR) and department from where the patients are included.
HF, heart failure; MR-proADM, mid-regional proadrenomedullin; NT-proBNP, aminoterminal pro-brain natriuretic peptide; NYHA, New York Heart Association; Ref, reference; eGFR, estimated glomerular filtration rate.